Datapoint: BMS to Battle AstraZeneca in Court Over Yervoy-Imjudo Dispute
Bristol Myers Squibb last week sued AstraZeneca in a Delaware federal court, alleging the drugmaker’s new Imjudo violates two of Yervoy’s patents. Imjudo, a CTLA-4 inhibitor, was granted FDA approval for the treatment of liver and lung cancer in 2022. Yervoy, meanwhile, is an oncology blockbuster, and was BMS’s No. 6 bestselling drug in 2021, bringing in $2.03 billion in sales. As a systemic therapy for non-small cell lung cancer (NSCLC) — one of Imjudo’s indications — Yervoy currently holds covered or better status for 66% of all insured lives under the pharmacy benefit, and 83% of lives under the medical benefit.
From Evaluate Pharma and MMIT Analytics, as of 1/25/23